Biotech | March 11, 2022
Emmes acquires Casimir, its fourth major acquisition
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
AOI is the leading cancer hospital chain of South Asia operating 16 cancer hospitals in the region
JEEN’s portfolio includes a diverse range of specialized active ingredients, botanical extracts, and complexes serving functional applications for skin and hair care
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Subscribe To Our Newsletter & Stay Updated
